



**Holger Moch**

**Kontakt**

Holger Moch

## Publikationen (41)

Gallon J, Rodriguez-Calero A, Benjak A, Akhoundova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Feng F, Gillessen S, Chiang C, Rubin M, Piscuoglio S. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations. *Cancer Res* 2023; 83:1203-1213.

Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Sellés Moreno C, Foegel M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. *Clin Cancer Res* 2022; 28:5368-5382.

Christiansen A, Lobo J, Fankhauser C, Rothermundt C, Cathomas R, Batavia A, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. *Front Oncol* 2022; 12:1056823.

Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins S, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Ng C, Gillessen S, Piscuoglio S, Rubin M. Alterations in homologous recombination repair genes in prostate cancer brain metastases. *Nat Commun* 2022; 13:2400.

Fankhauser C, Christiansen A, Rothermundt C, Cathomas R, Wettstein M, Grossmann N, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. *Br J Cancer* 2021; 126:1140-1144.

Marcu A, Walz J, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler M, Erhard F, Schlosser A, Kohlbacher O, Stevanovic S, Rammensee H, Kapolou K, Martin R, Hauri-Hohl M, Bichmann L, Kuchenbecker L, Kowalewski D, Freudenmann L, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Neidert M. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. *J Immunother Cancer* 2021; 9

Vital D, Ikenberg K, Moch H, Rössle M, Huber G. The expression of PD-L1 in salivary gland carcinomas. *Sci Rep* 2019; 9:12724.

Morand G, Ikenberg K, Vital D, Cardona I, Moch H, Stöckli S, Huber G. Preoperative assessment of CD44-mediated depth of invasion as predictor of occult metastases in early oral squamous cell carcinoma. *Head & neck* 2018; 41:950-958.

Zhong Q, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Rogel U, Vassella E, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey J, Wild P. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. *Pathol Res Pract* 2018; 214:957-963.

Vital D, Ikenberg K, Moch H, Roessle M, Huber G. The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading. *Laryngoscope Investig Otolaryngol* 2018; 3:182-190.

Fankhauser C, Moch H, Sulser T, Poyet C, Hermanns T, Rueschoff J, Rupp N, Omlin A, Gillessen Sommer S, Schöffler P, Wild P. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. *Oncotarget* 2017; 9:10284-10293.

Vital D, Huber G, Holzmann D, Moch H, Ikenberg K. The presence of aberrant p53 pattern is a negative prognostic predictor in squamous cell carcinoma of the nasal vestibule. *Eur Arch Otorhinolaryngol* 2017; 274:3503–3512.

Vital D, Holzmann D, Huber G, Soyka M, Moch H, Zimmermann D, Ikenberg K. p16: A surrogate marker of high-risk human papillomavirus infection in squamous cell carcinoma of the nasal vestibule. *Head & neck* 2017; 39:1392–1398.

Zhong Q, Poyet C, Blattner M, Soldini D, Moch H, Rubin M, Noske A, Rüschoff J, Haffner M, Jochum W, Perner S, Buhmann J, Rüschoff J, Guo T, Gabrani M, Schöffler P, Rechsteiner M, Liu Y, Fuchs T, Rupp N, Fankhauser C, Wild P. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. *Sci Rep* 2016; 6:24146.

Fellmann J, Weisert J, Soltermann A, Morand G, Morra L, Moch H, Huber G, Probst R. *Helicobacter pylori* detected in pharyngeal and laryngeal pathologies in patients with proven gastric colonization. *Head & neck* 2013; 36:1562–6.

Tordella L, Moch H, Rössle M, Huber G, Fritzsche F, Tavassoli M, McKeon F, Lozano G, Goldin R, Zhong S, Ratnayaka I, Feller S, Doondea J, Pagotto A, Salter V, Koch S, Lu X. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. *Proc Natl Acad Sci USA* 2013; 110:17969–74.

Rössle M, Weber C, Züllig L, Jochum W, Stöckli S, Moch H, Huber G. EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas. *Histopathology* 2013; 63:271–8.

Brogliè Däppen M, Soltermann A, Rohrbach D, Haile S, Pawlita M, Studer G, Huber G, Moch H, Stöckli S. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. *Head & neck* 2013; 35:1698–706.

Fritzsche F, Fritzsche C, Soldini D, Caduff R, Tinguely M, Cassoly E, Moch H, Stewart A. Occupational health risks of pathologists – results from a nationwide online questionnaire in Switzerland. *BMC Public Health* 2012; 12:1054.

Gupta R, Gown A, Cabrera R, Salles P, Vankalakunti M, Zhou M, Hansel D, de Castro M, Bacchi C, Hes O, Jochum W, Osunkoya A, Moch H, Shah R, Billis A, Amin M. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. *Am J Surg Pathol* 2012; 36:1265–78.

Schoenewolf N, von Moos R, Schraml P, Gillessen Sommer S, Ochsenbein A, Simcock M, Moch H, Mihic-Probst D, Dummer R, Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. *Case Rep Oncol* 2012; 5:280–9.

Schraml P, Moch H, Schläppi M, Seifert B, Michielin O, Dummer R, Ochsenbein A, Simcock M, Mihic-Probst D, von Teichman A, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. *Oncol Rep* 2012

Morra L, Moch H, Schraml P, Kristiansen G, Sulser T, Diener P, Santimaria R, Duc Luu V, Casagrande S, Rechsteiner M, Soltermann A. Relevance of periostin splice variants in renal cell carcinoma. *Am J Pathol* 2011; 179:1513–21.

Varga Z, Moch H, Jochum W, Bosshard G, Kradolfer D, Noske A, Sun Y, Wang Z, Tubbs R, Öhlschlegel C. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. *Breast Cancer Res Treat* 2011

Huber G, Züllig L, Soltermann A, Roessle M, Haerle S, Studer G, Jochum W, Moch H, Stöckli S. Down regulation of E-Cadherin (ECAD) – a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. *BMC cancer* 2011; 11:217:1–8.

Butsch R, Wälti S, Schaerer S, Braun J, Korol D, Probst-Hensch N, Moch H, Kurrer M. Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. *Leuk Lymphoma* 2011; 52:1230–8.

Viehl C, Langer I, Gueller U, Zanetti-Dällenbach R, Moch H, Wight E, Oertli D, Zuber M. Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. *J Surg Oncol* 2011; 103:531–3.

Huber G, Albinger-Hegyí A, Soltermann A, Roessle M, Haerle S, Holzmann D, Moch H, Hegyí I. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. *Cancer* 2011; 117:4659–70.

Cima I, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, Aebersold R, Leippold T, Fuchs T, Schubert O, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. *Proc Natl Acad Sci USA* 2011; 108:3342–7.

Huber G, Fritzsche F, Züllig L, Storz M, K Haerle S, Jochum W, Stöckli S, Moch H. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. *Int J Cancer* 2010

Langer I, Gueller U, Viehl C, Moch H, Wight E, Harder F, Oertli D, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. *Indian J Surg Oncol* 2010; 1:59–67.

Albinger-Hegyí A, Moch H, Tinguely M, Rehrauer H, Probst-Hensch N, Iotzova G, Storz M, Schmid S, Stöckli S, Hegyí I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). *Int J Cancer* 2010; 126:2653–62.

Riener M, Moch H, Soltermann A, Jochum W, Clavien P, Probst-Hensch N, Pestalozzi B, Soll C, Fritzsche F, Kristiansen G. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. *Histopathology* 2010; 56:600–6.

Langer I, Gueller U, Viehl C, Moch H, Wight E, Harder F, Oertli D, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. *Ann Surg Oncol* 2009; 16:3366–74.

Riener M, Jochum W, Moch H, Fritzsche F, Wild P, Neuhaus P, Bahra M, Clavien P, Mullhaupt B, Hellerbrand C, Probst-Hensch N, Samaras P, Pestalozzi B, Breitenstein S, Soll C, Liewen H, Stenner F, Kristiansen G. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. *Hepatology (Baltimore, Md.)* 2009; 49:1602–9.

Riener M, Moch H, Clavien P, Hellerbrand C, Jungbluth A, Jin B, Knuth A, Soll C, Wild P, Jochum W. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. *International journal of cancer. Journal international du cancer* 2009; 124:352–7.

Langer I, Zuber M, Burger D, Infanger E, Uehlinger U, Wight E, Schnarwyler B, Bronz L, Oertli D, Hess T, Fehr M, Schaer G, Moch H, Koechli O, Berclaz G, Gueller U, Swiss Multicenter Study Group Sentinel Lymph Node in Breast Cancer. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. *Breast Cancer Res Treat* 2008; 113:129-36.

Langer I, Marti W, Gueller U, Moch H, Harder F, Oertli D, Zuber M. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. *Ann Surg* 2005; 241:152-8.

Glatzel M, Stamm B, Podvinec M, Moch H, Huber G, Wüst W, Gmür A, Gebbers J, Linder T, Ott P, Aguzzi A. Human prion diseases: epidemiology and integrated risk assessment. *Lancet Neurol* 2003; 2:757-63.

Gueller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients?. *J Natl Cancer Inst* 2003; 95:1040-3.

Gueller U, Harder F, Oertli D, Marti W, Langer I, Moch H, Torhorst J, Viehl C, Schirp U, Nitzsche E, Zuber M. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!. *Breast Cancer Res Treat* 2002; 71:171-3.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)